Model-Informed Approaches to Support Drug Development for Patients With Obesity: A Regulatory Perspective.
J Clin Pharmacol
; 63 Suppl 2: S65-S77, 2023 11.
Article
en En
| MEDLINE
| ID: mdl-37942906
ABSTRACT
Obesity, which is defined as having a body mass index of 30 kg/m2 or greater, has been recognized as a serious health problem that increases the risk of many comorbidities (eg, heart disease, stroke, and diabetes) and mortality. The high prevalence of individuals who are classified as obese calls for additional considerations in clinical trial design. Nevertheless, gaining a comprehensive understanding of how obesity affects the pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of drugs proves challenging, primarily as obese patients are seldom selected for enrollment at the early stages of drug development. Over the past decade, model-informed drug development (MIDD) approaches have been increasingly used in drug development programs for obesity and its related diseases as they use and integrate all available sources and knowledge to inform and facilitate clinical drug development. This review summarizes the impact of obesity on PK, PD, and the efficacy of drugs and, more importantly, provides an overview of the use of MIDD approaches in drug development and regulatory decision making for patients with obesity estimating PK, PD, and efficacy in specific dosing scenarios, optimizing dose regimen, and providing evidence for seeking new indication(s). Recent review cases using MIDD approaches to support dose selection and provide confirmatory evidence for effectiveness for patients with obesity, including pediatric patients, are discussed. These examples demonstrate the promise of MIDD as a valuable tool in supporting clinical trial design during drug development and facilitating regulatory decision-making processes for the benefit of patients with obesity.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Desarrollo de Medicamentos
/
Obesidad
Límite:
Child
/
Humans
Idioma:
En
Revista:
J Clin Pharmacol
Año:
2023
Tipo del documento:
Article
País de afiliación:
Estados Unidos